Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 10c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.44 -0.71%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.30, $0.10 better than the analyst estimate of $4.20. Revenue for the quarter came in at $932.9 million versus the consensus estimate of $902.46 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.70-$17.71, versus the consensus of $17.09. Jazz Pharmaceuticals sees FY2022 revenue of $3.5-3.7 billion, versus the consensus of $3.6 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Cabot Corp. (CBT) Tops Q4 EPS by 7c, Beats on Revenue; Offers FY EPS Guidance
- Douglas Dynamics (PLOW) Tops Q3 EPS by 6c; updates guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
